Our pick · CoQ10 (Ubiquinol)

Thorne CoQ10 100mg

Check priceBuy now →

CoQ10 (Ubiquinol)

A mitochondrial coenzyme critical for cellular energy production, with good evidence for heart health support and addressing statin-related depletion.

By editorialUpdated 2026-05-254 min read

What it's actually good for

If you are over 40, or if you take a statin, pay attention to this one.

CoQ10 (coenzyme Q10) sits at the center of how your cells produce energy. It is embedded in the inner mitochondrial membrane, where it shuttles electrons in the respiratory chain — the process that generates roughly 95% of your body's ATP. Every cell that requires energy, which is every cell, depends on CoQ10 to function.

Here is the problem: your body's CoQ10 production peaks around age 20 and declines steadily thereafter. By middle age, levels in the heart muscle — one of the most energy-demanding tissues in the body — can drop by 30-40% compared to peak. This is a natural part of aging, and for most people it never becomes clinically apparent.

But then add statins to the picture. Statins work by inhibiting HMG-CoA reductase, the enzyme responsible for cholesterol synthesis. The catch is that the same enzyme sits upstream of CoQ10 synthesis. When you block it to lower cholesterol, you also reduce CoQ10 production as a collateral effect. Millions of people take statins. Many of them experience muscle pain and fatigue. And a measurable percentage of that may be related to CoQ10 depletion.

This isn't speculative biochemistry — it's been confirmed in human studies showing statins reduce circulating CoQ10 levels by 16-40%. Whether supplementing CoQ10 reliably fixes statin-related symptoms is a more complicated question, but the biological rationale is among the strongest in supplement science.

What the research says

Heart failure support (Grade B)

The strongest clinical evidence for CoQ10 comes from the Q-SYMBIO trial, published in 2014 by Mortensen et al. This was a well-designed, randomized, double-blind, placebo-controlled trial that followed 420 patients with chronic heart failure for two years. Patients received either 300 mg/day of CoQ10 or placebo in addition to standard treatment.

The results were striking: the CoQ10 group had a 43% reduction in cardiovascular mortality and a 42% reduction in all-cause mortality. Major adverse cardiovascular events were cut in half. These are meaningful numbers in a population with limited treatment options.

The trial wasn't perfect — 420 patients is moderate, and it took multiple years to reach significance — but it remains the best-designed CoQ10 heart failure trial to date. Additional meta-analyses support modest blood pressure reduction with CoQ10 supplementation, particularly in hypertensive patients.

This earns a B rather than an A because the evidence, while strong from Q-SYMBIO, hasn't been replicated in an equally large independent trial, and the effect on general cardiovascular health (as opposed to diagnosed heart failure) is less clear.

Statin-induced depletion and muscle symptoms (Grade B)

The biochemistry here is straightforward: statins inhibit the mevalonate pathway, which produces both cholesterol and CoQ10. Blood CoQ10 levels drop measurably in statin users. The clinical question is whether restoring those levels with supplements actually relieves statin-associated myalgia (muscle pain).

A 2018 meta-analysis in Mayo Clinic Proceedings pooled 12 RCTs and found a modest but statistically significant reduction in muscle pain scores with CoQ10 supplementation. However, individual trial results varied — some showed clear benefit, others didn't. This inconsistency keeps it at a B. That said, given the strong mechanistic basis, the good safety profile, and the low cost, many clinicians consider CoQ10 a reasonable addition for statin users experiencing muscle symptoms.

Migraine prevention (Grade C)

Several small RCTs have investigated CoQ10 for migraine prevention, with mixed results. The most positive was a 2005 trial by Sandor et al. that found 300 mg/day of CoQ10 reduced migraine frequency by nearly half compared to placebo. But the trial included only 42 patients, and other studies have been less consistently positive.

Some neurology guidelines list CoQ10 as "possibly effective" for migraine prophylaxis, alongside magnesium and riboflavin. The mitochondrial energy hypothesis of migraine provides a plausible mechanism. But the evidence isn't strong enough for a confident recommendation — it's worth trying if other approaches haven't worked, but expectations should be calibrated to a C grade.

How much, and which form

Dosing depends on the goal:

  • General supplementation / statin users: 100-200 mg/day.
  • Heart failure support: 200-300 mg/day (Q-SYMBIO used 300 mg/day).
  • Migraine prevention: 300-400 mg/day (based on trial protocols).

Split doses (2-3 times daily) may improve absorption at higher intakes. Always take CoQ10 with a meal that contains fat — it is fat-soluble and absorption increases substantially when taken with food versus on an empty stomach.

The ubiquinol vs. ubiquinone question is real. CoQ10 exists in two forms: ubiquinone (the oxidized form) and ubiquinol (the reduced, active form). Your body converts between the two, but the conversion efficiency decreases with age. Ubiquinol has roughly twice the bioavailability of ubiquinone in pharmacokinetic studies, meaning you need about half the dose to achieve the same blood levels. For adults over 40 — particularly those supplementing for cardiovascular support — ubiquinol is generally the better choice. Ubiquinone is cheaper and still effective if the dose is adjusted upward.

Soft gel capsules with oil-based carriers are preferred over dry powder capsules for absorption. Some formulations add black pepper extract or other bioavailability enhancers, though the evidence for these additions is limited.

Safety & interactions

CoQ10 has an excellent safety profile. Doses up to 1,200 mg/day have been used in clinical trials without serious adverse effects. The most common side effects are mild gastrointestinal symptoms — nausea, reduced appetite, or loose stools — and these are uncommon. Some people report mild insomnia if CoQ10 is taken late in the day, which makes sense given its role in cellular energy production. Morning or midday dosing avoids this.

The important interactions:

  • Warfarin: CoQ10 has a chemical structure similar to vitamin K and may reduce the anticoagulant effect of warfarin. If you take warfarin, work with your clinician and monitor INR closely when starting or stopping CoQ10.
  • Blood pressure medications: CoQ10 may modestly lower blood pressure, potentially enhancing the effect of antihypertensives. Monitor if you're already on BP medication.
  • Diabetes medications: CoQ10 may lower blood sugar slightly. Relevant if you're on insulin or oral hypoglycemics.
  • Chemotherapy: Some chemotherapy agents interact with CoQ10 — always consult your oncologist before supplementing during cancer treatment.

This is informational, not medical advice — check with a clinician before starting, especially if pregnant, nursing, on medication, or managing a chronic condition.

How we picked the brand

We prioritize the ubiquinol form for its superior bioavailability, particularly relevant for the over-40 demographic most likely to benefit from CoQ10. The product must deliver an adequate dose per capsule (100-200 mg ubiquinol), use an oil-based soft gel for absorption, and pass independent third-party testing for purity and potency. We avoid products with unnecessary fillers, proprietary blends, or unsubstantiated bioavailability claims. (Specific brand pick pending a current test-pass verification — see frontmatter.)

Claim-by-claim

Each claim graded independently

The overall grade is the floor. Some claims are stronger or weaker than the headline.

B

Supports cardiovascular function, particularly in heart failure

The Q-SYMBIO trial (420 patients, 2 years) showed CoQ10 supplementation significantly reduced major adverse cardiovascular events and all-cause mortality in chronic heart failure. Additional RCTs support modest blood pressure reduction (~11/7 mmHg in a meta-analysis of hypertensive patients). Evidence is strong but limited to specific cardiovascular conditions rather than general heart health.

B

Addresses statin-induced CoQ10 depletion and may reduce statin-associated muscle symptoms

Statins inhibit HMG-CoA reductase, the same pathway used for CoQ10 synthesis, measurably lowering blood CoQ10 levels. Some RCTs show CoQ10 supplementation reduces statin-associated myalgia, but results are mixed — a 2015 meta-analysis found modest benefit while individual trials vary. The biochemical rationale is solid even where symptom relief is inconsistent.

C

May help prevent migraines

Several small RCTs have found CoQ10 reduces migraine frequency, including a positive trial by Sandor et al. (2005) showing a significant reduction in attack frequency at 300 mg/day. However, trial sizes are small, results are mixed across studies, and a definitive meta-analysis is lacking. Some neurology guidelines include CoQ10 as a 'possibly effective' option.

Sources

5 cited
[04]RCTEfficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trialSandor PS, Di Clemente L, Coppola G, et al.. Neurology. 2005
[05]GOVTCoenzyme Q10National Center for Complementary and Integrative Health (NCCIH). 2024

When the evidence changes, we’ll tell you.

One short email a month. New A-grades, downgraded claims, and reader questions.

Medical disclaimer. The information on this site is provided for educational purposes only and is not intended as medical advice. It does not constitute a diagnosis, treatment plan, or recommendation for any specific health condition. Always consult a qualified healthcare professional before making changes to your supplement regimen, diet, or lifestyle — especially if you are pregnant, nursing, taking medications, or managing a medical condition.

Affiliate disclosure. Some links on this site are affiliate links. If you purchase through them, we may earn a small commission at no extra cost to you. This never influences our editorial assessments — products are graded solely on the evidence.